Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 9/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.38 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16631172 | 0.90 | CDA (0.37) | PNPSLC5A2SYNJ2ALDH1A1MEN1 | |
| SCHEMBL16631818 | 0.87 | PNP (0.35) | PNPSLC5A2ALDH1A1MEN1KMT2A | |
| SCHEMBL10764781 | 0.82 | PNP (0.44) | PNPSLC5A2 | |
| SCHEMBL18079930 | 0.77 | P2RY2 (0.49) | — | |
| SCHEMBL16631824 | 0.76 | SLC5A2 (0.44) | PNPSLC5A2SLC5A1 | |
| SCHEMBL14791302 | 0.75 | PNP (0.44) | PNPSLC5A2MAPTSMN1; SMN2 | |
| SCHEMBL10226283 | 0.75 | PNP (0.44) | PNPSLC5A2MAPTSMN1; SMN2 | |
| SCHEMBL21847661 | 0.75 | PNP (0.44) | PNPSLC5A2MAPTSMN1; SMN2 | |
| SCHEMBL17329460 | 0.75 | PNP (0.44) | PNPSLC5A2MAPTSMN1; SMN2 | |
| SCHEMBL15803217 | 0.75 | PNP (0.44) | PNPSLC5A2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | PNP 7/4885SLC5A2 3235/4885SLC5A1 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.